Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goodman

Showing results (931-940 of 1,119) with videos related to

Pageof 112
Sort By:
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|November 7, 2009
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)Jason P Linefsky, Min Lin, Karen S Pieper, et al.
American Heart Journal|November 14, 2017
Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysisJuan J Russo, Shaun G Goodman, Warren J Cantor, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trialsMina Madan, Sigrun Halvorsen, Carlo Di Mario, et al.
The Pharmacogenomics Journal|April 22, 2022
Point of care CYP2C19 genotyping after percutaneous coronary interventionLinnea M Baudhuin, Laura J Train, Shaun G Goodman, et al.
Journal of Clinical Lipidology|July 3, 2024
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES studyVera A Bittner, Gregory G Schwartz, Deepak L Bhatt, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
Circulation|August 26, 2023
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 TestsMichael Szarek, Esther Reijnders, J Wouter Jukema, et al.
Bone Marrow Transplantation|November 18, 1998
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerL A Holmberg, T Demirer, S Rowley, et al.
The Canadian Journal of Cardiology|June 1, 2022
Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMESChern-En Chiang, Gregory G Schwartz, Yedid Elbez, et al.
Pageof 112

Showing results (931-940 of 1,119) with videos related to

Sort By:
Pageof 112
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
The American Journal of Cardiology|November 7, 2009
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)Jason P Linefsky, Min Lin, Karen S Pieper, et al.
American Heart Journal|November 14, 2017
Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysisJuan J Russo, Shaun G Goodman, Warren J Cantor, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trialsMina Madan, Sigrun Halvorsen, Carlo Di Mario, et al.
The Pharmacogenomics Journal|April 22, 2022
Point of care CYP2C19 genotyping after percutaneous coronary interventionLinnea M Baudhuin, Laura J Train, Shaun G Goodman, et al.
Journal of Clinical Lipidology|July 3, 2024
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES studyVera A Bittner, Gregory G Schwartz, Deepak L Bhatt, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
Circulation|August 26, 2023
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 TestsMichael Szarek, Esther Reijnders, J Wouter Jukema, et al.
Bone Marrow Transplantation|November 18, 1998
High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancerL A Holmberg, T Demirer, S Rowley, et al.
The Canadian Journal of Cardiology|June 1, 2022
Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMESChern-En Chiang, Gregory G Schwartz, Yedid Elbez, et al.
Pageof 112